LSMS MEMBERS APPOINTED TO LOUISIANA PATIENTS COMPENSATION FUND (PCF) OVERSIGHT BOARD
PRESCRIPTION MONITORING PROGRAM ADVISORY COUNCIL
OPIOIDS FromCY2016 through CY2020, Louisiana saw a 29%decrease in the number of opioid prescriptions. Examining CY2021, it appears Louisiana is on track for another decrease in opioid prescriptions dispensed. The opioid prescriptions include all opiate agonist, opiate partial agonist, buprenorphine containing products used in medication assisted treatment, and antitussives containing opioids. CONTROLLED DANGEROUS SUBSTANCES FromCY2016 through CY2020, Louisiana saw a 17%decrease in the number of controlled substance prescriptions. Examining CY2021, it appears we will remain similar to CY2020 and perhaps see a slight decrease. The CDS prescriptions include all federally scheduled 2 through 5 prescriptions. It does not include Louisiana C-V, drugs of concern, or therapeutic marijuana recommendations. THERAPEUTIC MARIJUANA Reporting commenced in August of 2019. Through September 30, 2021, the total prescription count is 154,263 resulting from 280 prescribers and 28,174 patients.
LSMSVice President of Legal Affairs, LaurenBailey, serves as the Vice Chair of the Advisory Council which met on October 13, 2021, during which the council received an overview of the program operation including statistical information as follows: As of October 1, 2021, the Louisiana PMP is interoperable with 304 licensees representing more than 2,275 facilities responsible for over 1.9 million requests in the month of September. The PMP is sharing data with 35 PMPs including 1 federal district, 1 territory, 1 federal jurisdiction and 32 states. The most recent states to be added were Colorado and Rhode Island. NUMBER OF ELIGIBLE PRESCRIPTION TRANSACTIONS
Governor John Bel Edwards recently appointed Robert “Reece” Newsome, M.D., a Radiologist fromBaton Rouge and David M. Broussard, M.D., an Anesthesiologist from Metairie each to a four-year term on the Louisiana Patients Compensation Fund (PCF) Oversight Board. This will be the first term for each. Dr. Newsome and Dr. Broussard join Luis M. Alvarado (Internal Medicine – Mandeville) and Christopher M. Foret (Family Medicine – Folsom) on the PCF Board where Dr. Foret currently serves as the current Chairman.
Robert “Reece” Newsome, M.D.
REPORTED TO THE PMP The transactions include:
David M. Broussard, M.D
• controlled substances (schedules 2 through 5 federally),
• drugs of concern (butalbital, naloxone, promethazine in oral liquid formulations, and gabapentin containing products), • Louisiana C-V controlled substances (ephedrine, pseudoephedrine, phenylpropanolamine containing products), and
• therapeutic marijuana recommendations.
About the PCF Oversight Board It consists of a total of ninemembers who are representatives of one or more classes of health care providers enrolled in the fund and these members shall be apportioned according to the distribution of aggregate surcharges paid to the fund among the several classes of health care providers enrolled in the fund. Four of the members represent the providers contributing the greatest percentage of the aggregate surcharges, two members represent the second greatest percentage, one member represents the third greatest percentage, and one member is appointed to represent all other providers enrolled in the fund. The ninth member is selected from nominees from insurance agents and must be a La. Licensed producer with experience in property & casualty insurance. Board Members are appointed for 3-year terms. Members are paid $75 per diem when attending board meetings or when engaged in board business. They are also reimbursed for travel in accordance with the Louisiana travel regulations. The PCF’s regularly scheduled meetings are held on the first Thursday of each month at Our Lady of the Lake Regional Medical Center, Baton Rouge, LA. A representative from the LSMS is present at most meetings.
Examining the trajectory for CY2021, it appears we will have an increase in the number of prescriptions dispensed and reported to the PMP. However, after a careful review of the information, there has not been an increase in the number of prescriptions dispensed, instead the increase is the result of adding promethazine in oral liquid formulations and gabapentin containing products to the list of drugs of concern in January 2021 Pharmacies are now required to report these dispensed transactions to the PMP. This requirement has increased the number of prescriptions reported to the PMP by 1.25 million prescriptions thus far in 2021.
PAGE 8
PAGE 9
Made with FlippingBook Digital Publishing Software